Login / Signup

Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.

Frederik Hendrik VerbruggeAnne-Céline MartinDeborah SiegalKaren PieperLaura IllingworthA John CammKeith A A Fox
Published in: Heart (British Cardiac Society) (2019)
In contrast to guideline recommendations, almost half of real-world patients with AF at a very low thromboembolic risk according to the CHA2DS2-VASc score receive OAC. Persistent or permanent AF and increasing age up to 65 years are associated with OAC use, while concomitant antiplatelet therapy shows an inverse association. Regardless whether patients received OAC therapy, few thromboembolic and bleeding events occur, highlighting the low risk of this population.
Keyphrases